Business Context and Reporting Period
This Form 8-K Current Report from Ionis Pharmaceuticals, Inc. (IONS) covers events reported on March 3, 2026, with the report filed on March 9, 2026. The filing primarily addresses significant changes to the composition of the Company's Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- Departure of B. Lynne Parshall: Ms. Parshall, a Board member for over 25 years and former long-term executive (COO/CFO), notified the Company she will retire at the end of her term and not seek re-election at the 2026 Annual Meeting.
- Departure of Joseph H. Wender: Mr. Wender, the Lead Independent Director and Board member for over 32 years, notified the Company he will retire at the end of his term and not seek re-election at the 2026 Annual Meeting.
- Appointment of Peter N. Reikes: The Company announced that Peter N. Reikes will rejoin the Board of Directors on June 4, 2026. Mr. Reikes previously served on the Board from 2018-2021 and most recently served as a senior advisor to the FDA and the Advanced Research Projects Agency for Health.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, outlook, or specific risk factors. Regarding the new appointment, Mr. Reikes will receive standard non-employee director compensation (cash and automatic equity grants) and will enter into a standard indemnity agreement. The Company confirmed there are no other arrangements or understandings regarding his appointment.
Investor Verification Checklist
- Verify the exact date of the 2026 Annual Meeting of Stockholders to confirm the effective date of the retirements.
- Review the Company's Third Amended Non-Employee Director Compensation Policy (filed in the 2026 Form 10-K) to understand the specific equity and cash compensation for Mr. Reikes.
- Confirm the specific committee assignments for the new director, Mr. Reikes, once he joins the Board in June 2026.
- Monitor subsequent filings for the election results of the 2026 Annual Meeting.